Patents by Inventor Ernest C. Borden

Ernest C. Borden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
    Patent number: 9150920
    Abstract: Embodiments of the invention relate generally to ex vivo methods of quantifying expression of interferon responsive genes and characterizing an individual's potential responsiveness to interferon administration. Certain embodiments relate to methods to monitor the efficacy of ongoing interferon therapy by evaluating expression of interferon responsive genes before and after interferon administration.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: October 6, 2015
    Assignees: HITACHI CHEMICAL CO., LTD., HITACHI CHEMICAL COMPANY AMERICA, LTD, THE CLEVELAND CLINIC FOUNDATION
    Inventors: Masato Mitsuhashi, Ernest C. Borden
  • METHODS OF CHARACTERIZING HOST RESPONSIVENESS TO INTERFERON BY EX VIVO INDUCTION OF INTERFERON-RESPONSIVE MARKERS
    Publication number: 20130084577
    Abstract: Embodiments of the invention relate generally to ex vivo methods of quantifying expression of interferon responsive genes and characterizing an individual's potential responsiveness to interferon administration. Certain embodiments relate to methods to monitor the efficacy of ongoing interferon therapy by evaluating expression of interferon responsive genes before and after interferon administration.
    Type: Application
    Filed: May 3, 2011
    Publication date: April 4, 2013
    Applicants: HITACHI CHEMICAL CO., LTD., THE CLEVELAND CLINIC FOUNDATION, HITACHI CHEMICAL RESEARCH CENTER, INC.
    Inventors: Masato Mitsuhashi, Ernest C. Borden
  • Method of proliferating natural killer cells with IL-16
    Patent number: 5919700
    Abstract: The invention relates to a method of stimulating the proliferation of natural killer cells with in vitro IL-16. A mixed lymphocyte cell population which contains natural killer cells can be nylon wool-purified, and cultured in the presence of an effective amount of IL-16 to stimulate the proliferation of natural killer cells. Effective concentrations of IL-16 which enhance the proliferation of natural killer cells range from 1 ng/ml to 1000 ng/ml. Both the full length IL-16 protein or the naturally occurring carboxy terminal-truncated form of IL-16 are suitable for stimulating the proliferation of the natural killer cells. The IL-16 induced proliferation results in at least a five-fold enrichment of natural killer cells, and the natural killer cells can be subsequently isolated from the mixed lymphocyte culture.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: July 6, 1999
    Assignee: MCW Research Foundation
    Inventors: Ernest C. Borden, Jonathan D'Cunha
  • Production of IFN using DA15 peptide
    Patent number: 5418192
    Abstract: An in vitro method for the production of interferon is set forth. The method involves the culture of monocytes with a new DA15 peptide produced in Daudi cell lines in response to stimulation with interferon gamma.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: May 23, 1995
    Assignee: Medical College of Wisconsin Research Foundation
    Inventors: Ernest C. Borden, Michael Recht, Ernest Knight, Jr.
  • Method of reducing the level of low density lipoproteins in the serum of a patient
    Patent number: 4454115
    Abstract: A method is described for reducing the level of low density lipoproteins in the serum of a patient by administering to the patient human fibroblast interferon.
    Type: Grant
    Filed: October 23, 1981
    Date of Patent: June 12, 1984
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ernest C. Borden, Earl S. Shrago